Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Forevertek Biotechnology
Changsha, Hunan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Forevertek Biotechnology has demonstrated robust pre-clinical data for its CAR-T and bispecific antibody candidates. In multiple myeloma models, its anti-CS1 and anti-BCMA CAR-T cells showed complete inhibition of tumor growth and high cytokine secretion in vivo. Its bispecific CS1-BCMA CAR-T candidate has progressed into early-phase clinical assessment in China.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyBispecific monoclonal antibodyMonoclonal antibodyCell therapyNK cell therapyRecombinant protein
- Industry
- Biotech
02
Partnerships
ProMab BiotechnologiesGenoImmune (BGI Group)Antagene
Beyond the preview
Go deeper on Forevertek Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forevertek Biotechnology.